Background: The outbreak of severe acute respiratory syndrome β-coronavirus 2 (SARS-CoV-2) has the potential to become a long-lasting global health crisis. The number of people infected with the novel coronavirus has surpassed 22 million globally, resulting in over 700,000 deaths with more than 15 million people having recovered (https://covid19.who.int). Enormous efforts are underway for rapid vaccine and treatment developments. Amongst the many ways of tackling the novel coronavirus disease 2019 (COVID-19) pandemic, extracellular vesicles (EVs) are emerging. Summary: EVs are lipid bilayer-enclosed structures secreted from all types of cells, including those lining the respiratory tract. They have established roles in lung immunity and are involved in the pathogenesis of various lung diseases, including viral infection. In this review, we point out the roles and possible contribution of EVs in viral infections, as well as ongoing EV-based approaches for the treatment of COVID-19, including clinical trials. Key Messages: EVs share structural similarities to viruses and recent findings demonstrate that viruses exploit EVs for cellular exit and EVs exploit viral entry mechanisms for cargo delivery. Moreover, EV-virus interplay could be exploited for future antiviral drug and vaccine development. EV-based therapies, especially the mesenchymal stem cell-derived EVs, are being intensively studied for the treatment of COVID-19.
Plant-derived nanovesicles (NVs) have attracted interest due to their anti-inflammatory, anticancer and antioxidative properties and their efficient uptake by human intestinal epithelial cells. Previously we showed that tomato (Solanum lycopersicum L.) fruit is one of the interesting plant resources from which NVs can be obtained at a high yield. In the course of the isolation of NVs from different batches of tomatoes, using the established differential ultracentrifugation or size-exclusion chromatography methods, we occasionally observed the co-isolation of viral particles. Density gradient ultracentrifugation (gUC), using sucrose or iodixanol gradient materials, turned out to be efficient in the separation of NVs from the viral particles. We applied cryogenic transmission electron microscopy (cryo-TEM), scanning electron microscopy (SEM) for the morphological assessment and LC–MS/MS-based proteomics for the protein identification of the gradient fractions. Cryo-TEM showed that a low-density gUC fraction was enriched in membrane-enclosed NVs, while the high-density fractions were rich in rod-shaped objects. Mass spectrometry–based proteomic analysis identified capsid proteins of tomato brown rugose fruit virus, tomato mosaic virus and tomato mottle mosaic virus. In another batch of tomatoes, we isolated tomato spotted wilt virus, potato virus Y and southern tomato virus in the vesicle sample. Our results show the frequent co-isolation of plant viruses with NVs and the utility of the combination of cryo-TEM, SEM and proteomics in the detection of possible viral contamination.
1 May 2025 in International Journal of Nanomedicine
Purpose: Plant-derived nanovesicles (PDNVs) are promising candidates for next-generation drug delivery system due to their scalability, low cytotoxicity and immunogenicity, and efficient cellular uptake. Here, tomato fruit-derived PDNVs were loaded with tolvaptan, a vasopressin V2-receptor antagonist with the aim to reduce drug cytotoxicity, control drug release and to improve drug efficiency in vitro. Methods: Tolvaptan was encapsulated by extrusion and electroporation. Entrapment efficiency (EE%) and drug loading capacity (DLC%) were optimized by changing the drug-to-PDNV ratio and time-dependent drug release rate was evaluated at two different pH. Tolvaptan-loaded PDNVs were characterized using physiochemical and morphological methods. Cellular uptake of fluorescently labelled tolvaptan-loaded PDNVs was evaluated. The cytotoxicity and effects of tolvaptan-loaded PDNVs on cyst formation and cell migration were studied in different renal cell cultures. Results: Electroporation resulted in higher EE% and DLC% than extrusion for the encapsulation of tolvaptan into PDNVs. MDCK cells efficiently uptake tolvaptan-loaded PDNVs. The release of the tolvaptan was time and pH dependent. Enhanced cell proliferation, suppressed cyst growth, and altered cyst morphology compared with controls was observed. Migration assay demonstrated that tolvaptan-encapsulated PDNVs had a favourable effect on enhancing wound healing and cell migration in renal cells. Conclusion: Tolvaptan-loaded PDNVs show promising features as a natural next-generation nanoscale delivery system in vitro for time and pH-dependent release of hydrophobic drugs, such as tolvaptan.
Cloudberry nanovesicles (CNVs) remain stable under gastrointestinal conditions, efficiently cross intestinal barriers, and exhibit a favorable safety profile in both age groups, supporting their potential as oral drug delivery systems for all ages.
6 January 2025 in Journal of Pharmaceutical and Biomedical Analysis Open